The Effect on Lung Function of Budesonide and Fomoterol Fumarate Powder for Inhalation in Combination with Montelukast in the Treatment of Moderate and Severe Bronchial Asthma

OU Xiuyan; YUAN Xiaoling; GUO Weihong

Abstract：Objective To explore the effect on lung function of Budesonide and Fomoterol Fumarate Powder for Inhalation in combination with Montelukast in the treatment of moderate to severe bronchial asthma.Methods 85 patients with moderate and severe bronchial asthma were randomly selected and divided into observation group (45 cases) and control group (40 cases).Patients in the observation group received Budesonide and Fomoterol Fumarate Powder for Inhalation in combination with Montelukast (10 mg, MRK, once daily), while the control group received the Budesonide and Fomoterol Fumarate Powder for Inhalation only (160 μg/4.5 μg/snuff, AZN, twice daily), 12 weeks for each treatment.The clinical control effect and lung function were compared between the two groups before and after treatment in the 4, 8 and 12 weeks.Results There were no significant differences in control rate and ACT scores in the two groups before treatment (P>0.05).The control rate of observation group after 4 and 8 weeks is 91.11%and 93. 33%respectively, and the ACT scores are 23.17±4.87 and 25.31±3.61 respectively, which are significantly higher than those of the control group.There were significant differences in the two groups (P<0.05).There were no significant differencesafter 12 weeks of treatment (P>0.05).By the end of the course, there had been significant differences in FEV1, FEV1% and PEF% compared with the prior treatment ( P>0.05 ) , but there were no significant differences in the two groups ( P>0.05 ) .Conclusion Budesonide and Fomoterol Fumarate Powder for Inhalation in combination with Montelukast, with the unique advantages, prove to be obviously effective in controlling asthma in the early stage, improving the symptoms and reducing the recurrence rate.